Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(15 sites)

United States

University of California, Los Angeles, Los Angeles, California

University of California, San Francisco, San Francisco, California

Hartford Healthcare, Hartford, Connecticut

Community Health Network, Indianapolis, Indiana

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland